Search clinical trials for: TAK-831 Placebo

Total 58091 results

Basking Biosciences, Inc.

Not yet recruiting

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) (RAISE)

Acute Ischemic Stroke
Stealth BioTherapeutics Inc.

Terminated

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery (EVOLVE)

Renal Artery Obstruction | Ischemia Reperfusion Injury | Hypertension, Renovascular

United States
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Alzheimer's Disease
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Muscular Atrophy

Canada
Takeda

Completed

TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Takeda

Completed

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.

Chronic Insomnia

United States
Takeda

Completed

Efficacy and Safety of Ramelteon on Chronic Insomnia

Chronic Insomnia
Kallyope Inc.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes Mellitus (T2DM)

United States
China Medical University Hospital

Completed

Acupuncture for Blunt Chest Trauma

Chest Trauma | Rib Fractures

Taiwan
PPC Pharmaceuticals
Citruslabs

Completed

Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

Common Cold

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A First-In-Human Study of TAK-004 in Healthy Adults

Healthy Volunteers
Takeda

Completed

Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults

Influenza Infection
Cerevel Therapeutics, LLC

Recruiting

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Healthy Participants | Alzheimer's Disease Dementia

United States
Akros Pharma Inc.
ICON Clinical Research

Recruiting

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction (POWER-HF)

Chronic Heart Failure

United States
Eva Morava-Kozicz

Not yet recruiting

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

United States
Amgen

Completed

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura
Alzheon Inc.
Quotient Clinical

Completed

Multiple Ascending Dose Study of ALZ-801

Alzheimer Disease

United Kingdom
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Takeda
Nimbus Lakshmi, Inc.; Innovaderm Research Inc.

Completed

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Canada
Takeda

Withdrawn

A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder

Bipolar Disorder
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
Takeda

Recruiting

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Sleep Apnea

United States
Millennium Pharmaceuticals, Inc.

Withdrawn

Efficacy and Safety of TAK-653 in Treatment-Resistant Depression

Treatment-Resistant Depression
Takeda

Terminated

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Poland, Bulgaria, Romania, Canada, Hungary, Slovakia
Senju USA, Inc.

Completed

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

Chalazion

United States
Takeda

Completed

A Study of TAK-227 in Healthy Adults

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Calithera Biosciences, Inc

Terminated

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies

Advanced Nonhematological Neoplasms

Korea, Republic of, Japan, Taiwan
Takeda

Withdrawn

Bioavailability and Food Effect Study of Two Formulations of TAK-906

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Renal Impairment | Healthy Volunteers

Czechia, Hungary
Takeda

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954

Healthy Volunteers | Hepatic Impairment

Czechia, Slovakia
Takeda

Completed

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Healthy Participants

China
Millennium Pharmaceuticals, Inc.

Completed

A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

Carcinoma, Basal Cell | Advanced Nonhematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-901 in Adults With Advanced Solid Tumors or Lymphoma

Lymphoma | Advanced Solid Tumors

United States
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Takeda

Recruiting

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-103 in Adult With Solid Tumors

Solid Tumors

Japan
Takeda

Completed

A Study of Different Forms of TAK-994 in Healthy Adults

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Takeda

Completed

Open-label Study of TAK-875

Diabetes Mellitus

Japan
Takeda

Completed

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Breast Neoplasm | Ovarian Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Renal Neoplasm

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes Mellitus in Obese

United States
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Takeda

Recruiting

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan

3

Subscribe